Good evening :)
Place Order
Add to Watchlist

SMS Pharmaceuticals Ltd

SMSPHARMA Share Price

247.553.28% (-8.40)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹2,269 cr, stock is ranked 1,074

Stock is 4.02x as volatile as Nifty

SMSPHARMA Stock Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is not in the overbought zone

Red flags

Avg

The stock has a moderate number of red flags

How to use scorecard? Learn more

With a market cap of ₹2,269 cr, stock is ranked 1,074

Stock is 4.02x as volatile as Nifty

SMSPHARMA Performance & Key Metrics

SMSPHARMA Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
32.834.230.15%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
36.256.670.83%

SMSPHARMA Analyst Ratings & Forecast

Analyst Ratings data is currently unavailable for this stock

Price Upside

Earnings Growth

Rev. Growth

SMSPHARMA Company Profile

SMS Pharmaceuticals Limited is engaged in manufacturing and sale of bulk drugs and active pharmaceutical ingredients (APIs), and their intermediates.

Investor Presentation

View older View older 

Feb 12, 2025

PDF
View Older Presentations

SMSPHARMA Similar Stocks (Peers)

Compare with peers Compare with peers 

SMSPHARMA Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
37.04
37.04
1Y Return
11.72%
11.72%
Buy Reco %
87.88
87.88
PE Ratio
23.02
23.02
1Y Return
2.38%
2.38%
Buy Reco %
74.19
74.19
PE Ratio
20.05
20.05
1Y Return
11.76%
11.76%
Buy Reco %
56.67
56.67
PE Ratio
57.71
57.71
1Y Return
13.13%
13.13%
Buy Reco %
72.00
72.00
PE Ratio
49.54
49.54
1Y Return
6.30%
6.30%
Buy Reco %
81.25
81.25
Compare with Peers

SMSPHARMA Sentiment Analysis

SMSPHARMA Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

SMSPHARMA Stock Summary · June 2025

The company has demonstrated robust financial performance, with a remarkable 39% increase in Profit After Tax for FY '25, driven by strategic initiatives such as backward integration and a diversified product mix. Despite facing challenges like high inventory levels and pricing pressures, management remains optimistic about achieving a targeted 20% revenue growth and expanding EBITDA margins in FY '26, supported by a significant capital expenditure plan of INR 250 crores. The focus on high-volume APIs, particularly in the ibuprofen segment, is expected to enhance market share and profitability, with ambitious volume targets set to reach 5,000 tons. Overall, the company is well-positioned to capitalize on growth opportunities while navigating market dynamics effectively.

SMSPHARMA Stock Growth Drivers
SMSPHARMA Stock Growth Drivers
6
  • Strong Financial Performance

    The company reported a significant 39% growth in Profit After Tax (PAT) for FY '25,

  • Operational Milestones and Compliance

    The company achieved notable operational milestones, including the launch of Asia's largest dedicated automated production

SMSPHARMA Stock Challenges
SMSPHARMA Stock Challenges
4
  • High Inventory Levels

    The company is currently facing challenges due to high inventory levels, which amount to INR

  • Debt and Financial Burden

    The company has a significant debt of INR 311 crores, which incurs an annual interest

SMSPHARMA Forecast

SMSPHARMA Forecasts

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

SMSPHARMA

SMSPHARMA

Income

Balance Sheet

Cash Flow

SMSPHARMA Income Statement

SMSPHARMA Income Statement

Industry refers to the sub-sector this company belongs to.
Lower than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 8.79%, vs industry avg of 9.02%

Decreasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.21% to 0.19%

Lower than Industry Net Income
Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 4.47%, vs industry avg of 15.29%

Loading...

Financial YearFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Total Revenue439.58465.07468.31417.06566.62525.07526.96713.73788.97788.97
Raw Materialssubtract325.03294.32307.19259.50313.27387.95299.72425.26643.76643.75
Power & Fuel Costsubtract18.2322.5721.7518.9923.3132.5835.9747.12
Employee Costsubtract26.9232.8035.5939.3541.1751.0250.0856.78
Selling & Administrative Expensessubtract10.239.679.8410.1819.0221.1225.2835.68
Operating & Other expensessubtract-17.429.970.403.9045.27-87.4156.4627.66
Depreciation/Amortizationsubtract19.1819.9019.2722.0722.2832.1532.1331.5234.3434.34
Interest & Other Itemssubtract15.8215.4811.9212.3211.1919.1621.9723.6018.5418.55
Taxes & Other Itemssubtract13.0928.5922.3119.1828.606.2812.4116.2823.2023.21
EPS3.373.754.733.737.387.35-0.835.898.168.17
DPS0.200.250.250.250.300.300.300.400.400.40
Payout ratio0.060.070.050.070.040.040.070.050.05

SMSPHARMA Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2025FY 2025

Annual Report Pending

Investor Presentation

Feb 12PDF
Nov 12PDF
FY 2024FY 2024

Annual report

PDF

Investor Presentation

Aug 9PDF
FY 2023FY 2023

Annual report

PDF

Investor Presentation

May 25PDF
Nov 14PDF
Aug 13PDF
FY 2022FY 2022

Annual report

PDF

Investor Presentation

Jun 2PDF
Feb 10PDF
Nov 13PDF
Oct 28PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
FY 2016FY 2016

Annual report

PDF
FY 2015FY 2015

Annual report

PDF
 

SMSPHARMA Stock Peers

SMSPHARMA Past Performance & Peer Comparison

SMSPHARMA Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
SMS Pharmaceuticals Ltd32.824.230.15%
Sun Pharmaceutical Industries Ltd37.046.030.95%
Cipla Ltd23.024.531.06%
Dr Reddy's Laboratories Ltd20.054.010.59%

SMSPHARMA Stock Price Comparison

Compare SMSPHARMA with any stock or ETF
Compare SMSPHARMA with any stock or ETF
SMSPHARMA
Loading...

SMSPHARMA Holdings

SMSPHARMA Shareholdings

SMSPHARMA Promoter Holdings Trend

SMSPHARMA Promoter Holdings Trend

Increased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has increased by 1.59%

High Pledged Promoter Holding
Lower pledged promoter holdings is considered better

A significant proportion of promoter holdings is pledged

SMSPHARMA Institutional Holdings Trend

SMSPHARMA Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

SMSPHARMA Shareholding Pattern

SMSPHARMA Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding66.26%2.43%0.00%0.08%31.22%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

SMSPHARMA Shareholding History

SMSPHARMA Shareholding History

Dec '23MarJunSepDec '24Mar0.59%0.17%0.17%0.52%0.31%0.08%

Mutual Funds Invested in SMSPHARMA

Mutual Funds Invested in SMSPHARMA

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 3 Mutual Funds holding SMS Pharmaceuticals Ltd




Funds (Top 3)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
1.9343%0.17%0.04%91/112 (-1)
0.9721%5.29%1.63%14/27 (-1)
0.0005%0.06%0.01%91/109 (-2)

Compare 3-month MF holding change on Screener

SMSPHARMA Insider Trades & Bulk Stock Deals

SMSPHARMA Insider Trades & Bulk Stock Deals

Loading...

smallcases containing SMSPHARMA stock

smallcases containing SMSPHARMA stock

Looks like this stock is not in any smallcase yet.

SMSPHARMA Events

SMSPHARMA Events

SMSPHARMA Dividend Trend

No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year

SMSPHARMA has increased or maintained dividend levels over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.15%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.49 every year

Dividends

Corp. Actions

Announcements

Legal Orders

SMSPHARMA Dividend Trend

No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year

SMSPHARMA has increased or maintained dividend levels over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.15%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.49 every year

SMSPHARMA Upcoming Dividends

SMSPHARMA Upcoming Dividends

No upcoming dividends are available

SMSPHARMA Past Dividends

SMSPHARMA Past Dividends

Cash Dividend

Ex DateEx DateSep 23, 2024

Final
Final | Div/Share: ₹0.40

Dividend/Share

0.40

Ex DateEx Date

Sep 23, 2024

Cash Dividend

Ex DateEx DateSep 22, 2023

Final
Final | Div/Share: ₹0.30

Dividend/Share

0.30

Ex DateEx Date

Sep 22, 2023

Cash Dividend

Ex DateEx DateSep 22, 2022

Final
Final | Div/Share: ₹0.30

Dividend/Share

0.30

Ex DateEx Date

Sep 22, 2022

Cash Dividend

Ex DateEx DateSep 22, 2021

Final
Final | Div/Share: ₹0.30

Dividend/Share

0.30

Ex DateEx Date

Sep 22, 2021

Cash Dividend

Ex DateEx DateMar 26, 2020

Interim
Interim | Div/Share: ₹0.25

Dividend/Share

0.25

Ex DateEx Date

Mar 26, 2020

SMSPHARMA Stock News & Opinions

SMSPHARMA Stock News & Opinions

Corporate
Board of SMS Pharmaceuticals recommends final dividend

SMS Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 30 May 2025, inter alia, have recommended the final dividend of Rs 0.4 per equity Share (i.e. 40%) , subject to the approval of the shareholders.Powered by Capital Market - Live

1 week agoCapital Market - Live
Earnings
SMS Pharmaceuticals consolidated net profit rises 17.59% in the March 2025 quarter

Net profit of SMS Pharmaceuticals rose 17.59% to Rs 20.32 crore in the quarter ended March 2025 as against Rs 17.28 crore during the previous quarter ended March 2024. Sales rose 0.98% to Rs 248.20 crore in the quarter ended March 2025 as against Rs 245.80 crore during the previous quarter ended March 2024. For the full year,net profit rose 38.75% to Rs 69.14 crore in the year ended March 2025 as against Rs 49.83 crore during the previous year ended March 2024. Sales rose 10.36% to Rs 782.75 crore in the year ended March 2025 as against Rs 709.26 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales248.20245.80 1 782.75709.26 10 OPM %16.4413.67 -17.7616.44 - PBDT37.1629.65 25 126.6797.62 30 PBT28.5221.74 31 92.3466.11 40 NP20.3217.28 18 69.1449.83 39 Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
SMS Pharmaceuticals to announce Quarterly Result

SMS Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 30 May 2025.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
SMS Pharmaceuticals' Unit VII receives WHO Geneva prequalification

SMS Pharmaceuticals announced that Unit VII manufacturing facility in Visakhapatnam, Andhra Pradesh, has received prequalification approval from the World Health Organisation (WHO) Geneva. The company added, This significant milestone enhances our global regulatory standing and enables the company to increase its presence in the global market for Anti-Retroviral (ARV) APIs. Commenting on this achievement,  P. Vamsi Krishna, Executive Director, stated: 'The WHO Geneva prequalification reflects the company's strong compliance with stringent international regulatory standards, reinforcing its reputation for quality, reliability, and global competitiveness.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
SMS Pharma gains after Hyderabad facility completes USFDA inspection

According to an exchange filing, the inspection was conducted from 17 March to 21 March 2025 and concluded with one observation in Form 483. The observation was procedural in nature and does not relate to data integrity or product quality. The company will provide the necessary response to USFDA within the stipulated period. The Hyderabad facility has a manufacturing capacity of 120 KL, specializing in niche small-volume and high-value molecules. It holds multiple regulatory approvals, including USFDA, EU GMP, KFDA, ANVISA, PMDA, and CDSCO. P. Vamsi Krishna, executive director, stated, The successful completion of the USFDA inspection underscores our commitment to quality, compliance, and global regulatory standards. This is the 6th USFDA inspection for this facility, reflecting our team's dedication to maintaining the highest manufacturing practices. This milestone further strengthens our reputation as a trusted partner in the pharmaceutical industry, ensuring an uninterrupted supply of high-quality APIs to key international markets. The official announcement was made on Friday, 21 March 2025, after market hours. SMS Pharmaceuticals is a diversified and integrated pharmaceutical company specializing in APIs and intermediates for global customers. The company operates two state-of-the-art manufacturing facilities in Hyderabad and Vizag, with capacities of 120 KL and 3,000 KL, respectively. The company has a proven track record of delivering quality products across a diversified portfolio of therapeutic segments, serving as a trusted partner to a global customer base in over 70 countries. The company's consolidated net profit surged 58.9% to Rs 18.24 crore in Q3 FY25 as against Rs 11.48 crore recorded in Q3 FY24. Revenue from operations rose 7.4% to Rs 173.35 in the quarter ended 31 December 2024. Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
SMS Pharma's Hyderabad facility completes USFDA inspection with 1 observation

According to an exchange filing, the inspection was conducted from 17 March to 21 March 2025 and concluded with one observation in Form 483. The observation was procedural in nature and does not relate to data integrity or product quality. The company will provide the necessary response to USFDA within the stipulated period. The Hyderabad facility has a manufacturing capacity of 120 KL, specializing in niche small-volume and high-value molecules. It holds multiple regulatory approvals, including USFDA, EU GMP, KFDA, ANVISA, PMDA, and CDSCO. P. Vamsi Krishna, executive director, stated, The successful completion of the USFDA inspection underscores our commitment to quality, compliance, and global regulatory standards. This is the 6th USFDA inspection for this facility, reflecting our team's dedication to maintaining the highest manufacturing practices. This milestone further strengthens our reputation as a trusted partner in the pharmaceutical industry, ensuring an uninterrupted supply of high-quality APIs to key international markets. SMS Pharmaceuticals is a diversified and integrated pharmaceutical company specializing in APIs and intermediates for global customers. The company operates two state-of-the-art manufacturing facilities in Hyderabad and Vizag, with capacities of 120 KL and 3,000 KL, respectively. The company has a proven track record of delivering quality products across a diversified portfolio of therapeutic segments, serving as a trusted partner to a global customer base in over 70 countries. The company's consolidated net profit surged 58.9% to Rs 18.24 crore in Q3 FY25 as against Rs 11.48 crore recorded in Q3 FY24. Revenue from operations rose 7.4% to Rs 173.35 in the quarter ended 31 December 2024. The counter advanced 2.16% to end at Rs 217.90 on the BSE on Friday. Powered by Capital Market - Live

2 months agoCapital Market - Live
Earnings
SMS Pharmaceuticals consolidated net profit rises 58.89% in the December 2024 quarter

Net profit of SMS Pharmaceuticals rose 58.89% to Rs 18.24 crore in the quarter ended December 2024 as against Rs 11.48 crore during the previous quarter ended December 2023. Sales rose 7.35% to Rs 173.35 crore in the quarter ended December 2024 as against Rs 161.48 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales173.35161.48 7 OPM %19.1617.96 - PBDT31.1324.54 27 PBT22.4416.53 36 NP18.2411.48 59 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
SMS Pharmaceuticals schedules board meeting

SMS Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 February 2025.Powered by Capital Market - Live

4 months agoCapital Market - Live
Earnings
SMS Pharmaceuticals consolidated net profit rises 20.20% in the September 2024 quarter

Net profit of SMS Pharmaceuticals rose 20.20% to Rs 14.10 crore in the quarter ended September 2024 as against Rs 11.73 crore during the previous quarter ended September 2023. Sales rose 18.07% to Rs 196.75 crore in the quarter ended September 2024 as against Rs 166.64 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales196.75166.64 18 OPM %15.9916.69 - PBDT28.1623.06 22 PBT19.5415.16 29 NP14.1011.73 20 Powered by Capital Market - Live

7 months agoCapital Market - Live
Corporate
SMS Pharmaceuticals to convene board meeting

SMS Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 8 November 2024Powered by Capital Market - Live

7 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of SMS Pharmaceuticals Ltd (SMSPHARMA) today?

    The share price of SMSPHARMA as on 13th June 2025 is ₹247.55. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on SMS Pharmaceuticals Ltd (SMSPHARMA) share?

    The past returns of SMS Pharmaceuticals Ltd (SMSPHARMA) share are
    • Past 1 week: 2.07%
    • Past 1 month: 4.47%
    • Past 3 months: 29.70%
    • Past 6 months: 0.14%
    • Past 1 year: 18.42%
    • Past 3 years: 212.37%
    • Past 5 years: 349.27%

  3. What are the peers or stocks similar to SMS Pharmaceuticals Ltd (SMSPHARMA)?
  4. What is the dividend yield % of SMS Pharmaceuticals Ltd (SMSPHARMA) share?

    The current dividend yield of SMS Pharmaceuticals Ltd (SMSPHARMA) is 0.15.

  5. What is the market cap of SMS Pharmaceuticals Ltd (SMSPHARMA) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of SMS Pharmaceuticals Ltd (SMSPHARMA) is ₹2269.05 Cr as of 13th June 2025.

  6. What is the 52 week high and low of SMS Pharmaceuticals Ltd (SMSPHARMA) share?

    The 52-week high of SMS Pharmaceuticals Ltd (SMSPHARMA) is ₹398 and the 52-week low is ₹176.05.

  7. What is the PE and PB ratio of SMS Pharmaceuticals Ltd (SMSPHARMA) stock?

    The P/E (price-to-earnings) ratio of SMS Pharmaceuticals Ltd (SMSPHARMA) is 32.82. The P/B (price-to-book) ratio is 4.23.

  8. Which sector does SMS Pharmaceuticals Ltd (SMSPHARMA) belong to?

    SMS Pharmaceuticals Ltd (SMSPHARMA) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  9. How to buy SMS Pharmaceuticals Ltd (SMSPHARMA) shares?

    You can directly buy SMS Pharmaceuticals Ltd (SMSPHARMA) shares on Tickertape. Simply sign up, connect your demat account and place your order.